In a rapidly evolving world where scientific breakthroughs are essential for the betterment of healthcare, MoleculeAI stands at the forefront, pioneering t...
– Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studie...
Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) announced a change of the Company’s name to Elutia Inc. The rebranding reflects the ...
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among childre...
Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colo...
“Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opd...
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With...
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prosta...
The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patie...
OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein α (FAPα). FAPα is a dimeric type ...
ImmunoGen to Receive $34 Million1 in Upfront and Near-Term Milestone Payments and is Eligible to Receive Potential Regulatory and Commercial Milestone Paym...
The world of drug discovery is about to get a major boost as two cutting-edge technologies join forces. The integration of Serengen's unrivalled DEL techno...
The HD-MAP platform technology offers user-friendly vaccines, allowing possible self-administration. Its room temperature stability revolutionizes distri...
Abrysvo is administered as a single dose injection into the muscle. The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals...
© 2025 Biopharma Boardroom. All Rights Reserved.
